Key facts
- It has raised $250K; the latest was Later Stage VC in Mar 2025.
- Notable investors include MassChallenge, SOSV, Dorm Room Fund, IndieBio, Third Kind Venture Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Nivien Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nivien Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nivien Therapeutics
Developer of the first small molecule drugs designed to enhance both chemo and immunotherapies. The company's program de-risks transfers of tech assets from top research institutes, it is also developing a novel platform to enhance IO-chemo combo therapies for treatment-resistant cancers. enabling research institutes to build a portfolio of ROI biotech investments.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Employees
- 5
- Website
- nivientherapeutics.com/
- Ownership
- Privately Held (backing)
Nivien Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nivien Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nivien Therapeutics in its N-PORT filings yet. We sweep new filings monthly.